Relating to restrictions on 340B covered entities.

Creates a civil penalty for drug manufacturers that interfere directly or indirectly with certain entities acquiring 340B drugs, delivering 340B drugs to certain health care providers or dispensing 340B drugs. Creates a civil penalty for drug manufactures that require certain entities to submit utilization review data as a condition of acquiring, delivering or dispensing 340B drugs.